New ‘saliva test’ to instantly detect COVID-19 coronavirus with lasers
07 April 2020
Colour graphic image of the ‘nanophotonic biosensor’ operating in the evanescent field [image credit: CONVAT]
European photonics scientists are developing an ultrasensitive laser sensor that detects coronavirus at the earliest point of infection from a saliva or nasal swab in just minutes.
Responding to the European Commission’s Express Calls to tackle the coronavirus pandemic, photonics scientists are developing a new rapid, non-invasive ‘optical biosensor’ demonstrator that will detect COVID-19 in humans as soon as it is present in the body.
Having already created six working laboratory demonstrators for other applications, the research team says the technology still needs further adaptation and testing, but could be available in a year at the latest.
Originally developed to look for bacterial infections or cancer biomarkers, the new ultrasensitive detector uses photonics – technology that manipulates light – to detect infections in patients with a small amount of the virus.
With the ability to diagnose in real-time, with high specificity from a low concentration sample, the sensor is much more reliable than the coronavirus rapid-test ‘finger-prick’ kit, which detects if a person has had the coronavirus before and has since recovered.
Looking at tiny molecules, the new point-of-care detector examines virus antigens using miniaturised chips – or ‘nanophotonic biosensors’ – from a simple nasal or saliva swab.
Once a sample is prepared and is in place, the device confirms a positive or negative for coronavirus instantaneously. However, allowing for preparation time and analysis, a result – from sample to diagnosis – may take up to 30 minutes.
Calling themselves CONVAT and coordinated at ‘ICN2’ (the Catalan Institute of Nanoscience & Nanotechnology, Spain), the researchers have tested the demonstrators on patients’ samples provided by Vall D´Hebrón Hospital in Barcelona, and several other hospitals in Spain for other pathologies.
Project coordinator, Professor Laura Lechuga said: “With thousands of deaths worldwide, we are in urgent need of a rapid new testing kit that is accurate, highly sensitive, non-invasive and cheap to produce.
“We are currently integrating all the instrumentation in a portable 25x15x25cm box with a tablet control. At present, our detector is user-friendly, with the preparation being only technical expertise required, and could be widely deployed for GPs or nurses to test patients.
“Our nanosensor is capable of detecting RNA strands which will fully identify the new coronavirus.”
Unique interferometric technology
The detector works by looking at the ‘binding’ of the coronavirus molecules to the sensor surface – producing a new signal when the virus is present.
The CONVAT team use a Nano-Interferometric Biosensor, the most sensitive, label-free detection technology available in the world today – identifying at the molecular level.
Since the bioreceptors on the sensor surface are specifically ‘tuned’ to a particular antigen of the virus, only the coronavirus molecules are captured along the sensor.
Light travelling in the sensor generates an evanescent field of few nanometres over the sensor surface. Here, receptors (like antibodies or DNA strands) can recognise the antigens of the virus capsid, when a respiratory fluid sample passes through.
This recognition event produces a change in the refractive index, causing the light to slightly change its direction of travel.
This change can be measured and determined precisely against a set of existing values – and could give an instant diagnosis for coronavirus expected at the picomolar to attomolar (pM–aM) range, without any need amplification.
Professor Lechuga said: "Our patented interferometric technology is unique for biosensing. We use our “Bimodal Waveguide interferometer” which uses two modes of a light beam (at the visible wavelength) travelling in a single waveguide.
CONVAT laboratory at the ‘ICN2’ (the Catalan Institute of Nanoscience & Nanotechnology, Spain) [image credit: CONVAT]
“The light interacts with analytes during their travel and at the end of the bimodal waveguide, we record the interference between both light modes. The signal is collected with a photodetector and processed by electronics, all instantly in real-time.”
“Photonics is renowned for its rapid, stand-off and clean detection capabilities, so it made perfect sense to develop a device that exploited light amid this terrible pandemic,” said Professor Lechuga.
With thousands of new cases reported each day, COVID-19 is a novel coronavirus that had not previously been present in humans. While it is not known exactly how the virus is spreading from person to person, it is thought the outbreak – similar to the 2002 SARS coronavirus – may have spread via cough and sneeze droplets.
“Our nanophotonic POC biosensor can examine respiratory body fluids for rapid diagnostics and screening. It looks directly at the human or animal reservoir samples, without the need for PCR or other time-consuming treatments.
“In our previous work, we demonstrated sensitivities at the attomolar (aM) level for direct specific miRNA detection and 4 CFU/mL for whole pathogen detection.
“While our previous results are promising, our sensor will be further optimised and evaluated also for viral RNA analysis in a multiplexed format for more accurate diagnosis and identification of virus strains among different coronaviruses and other clinically relevant viruses,” Professor Lechuga said.
Chair of the Photonics21 Healthcare Workgroup, Dr Jurgen Popp said: “The CONVAT team are working round the clock to develop a rapid, non-invasive test for coronaviruses. The ability to spot this terrible virus quickly will contribute to the worldwide effort in fighting 2019-nCoV, and highlights yet another success for photonics and light technologies.”
Philippe Vannson, Head of the Photonics Unit, DG CONNECT, at the European Commission said: “Light-based technologies are providing tools and solutions to every industry in every region in the world. By creating instant diagnosis of major diseases photonics is making healthcare fast, precise and cost-effective.”
The technology to be employed in the coronavirus detector was a pre-existing piece of apparatus, developed by Dr Lechuga to examine different pathologies, like bacterial infections, or cancer biomarkers. However, in response to the 2019-nCoV pandemic, the researchers knew their technology could be modified to detect early, low viral load cases:
“My colleague, a researcher from the University of Barcelona, who has worked on the surveillance of Coronaviruses in animal reservoirs for many years, often suggested that we should work together on a project. So when we saw the Express Call for proposals, one of the specific Coronavirus fighting calls – with a deadline of 30 Jan 2020, I telephoned him and said, now is the time to work together.
“In just eight days, we worked more than 12 hours per day to put together a consortium of four partners, writing a successful proposal to the EC. It was approved, and now I’ve been contacted by the Spanish Minister for Science & Innovation, and invited onto TV and radio talk shows.”
Funded by Horizon 2020, the European Commission’s scientific research initiative, the scientists only began work on their detector at the start of March, in response to the pandemic.
Photonics21 is the European Technology Platform (ETP) for photonics, a technology encompassing all of the products and processes around the emission, manipulation and detection of light. Photonics is integral to a wide range of industries that include the medical, healthcare, transport, manufacturing and telecommunications sectors.
"Photonics21" was set up in December 2005 to bring the community of photonics researchers and industries together. The European Commission defined photonics as one of five European Key Enabling Technologies (KETs) in September 2009. Shortly after, the European Research & Innovation Program "Horizon 2020" invited Photonics21 to become a "Public-Private Partnership" (PPP). The "Photonics 21 Association", a legal entity under Belgium law, became the private contract partner in November 2013 in a Public-Private Partnership (PPP) in conjunction with the EU Commission.
Today Photonics21 represents more than 3000 personal members from across Europe and abroad. Our members are experts in the photonics industry, research organisations and universities who actively engage with us to develop a joint photonics strategy for future research and innovation in Europe.
With the global photonics market growing from €350 Billion in 2011 to €447 Billion in 2015, Photonics remains a strong industry. The European photonics industry, estimated to be worth €70 billion, has considerable global leadership positions and employs over 300,000 people directly.
Contact Details and Archive...